Back to Research Hub
Tarsus Pharmaceuticals, Inc.
TARS
$61.55+1.91 (+3.20%)
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions.
StreetsValue research for Tarsus Pharmaceuticals, Inc. (TARS)
Members get the full report for Tarsus Pharmaceuticals, Inc.: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.